The FDA's 2024 approval of the Farapulse system covered patients with paroxysmal atrial fibrillation. Now, however, the technology is officially approved for patients with more persistent symptoms. 

While Kardium raised $250 million in an oversubscribed funding round, Field Medical raised $35 million. Both companies are focused on designing and developing new pulsed field ablation technologies to help treat challenging arrhythmias. 

After being ordered to pay $442 million in damages—a ruling the company has said it may appeal—Johnson & Johnson MedTech is now facing the possibility of a permanent injunction that could impact certain business practices. A hearing is scheduled for July. 

The San Diego-based startup gained FDA approval for its Hotwire RF guidewire in 2024. The technology has already been used to perform hundreds of heart procedures.

A bad outcome for Johnson & Johnson MedTech just got worse. A jury previously ordered the company to pay $147M, but the new total is $442M.

Clinical guidelines already recommend that these procedures be performed together when applicable. However, researchers noted, it is still not terribly common among today’s surgeons. 

The company says the new device was designed to improve image quality, provide additional maneuverability and simplify ablation workflows for electrophysiologists. 

The company told Cardiovascular Business it respectfully disagrees with the jury's decision and is evaluating all possible legal options going forward. The Association of Medical Device Reprocessors, meanwhile, celebrated the news.